<DOC>
	<DOCNO>NCT00284193</DOCNO>
	<brief_summary>Patients severe hemophilia inhibitor treat effectively Activated Prothrombin Complex Concentrates ( APCC , eg . FEIBA ) High dose recombinant factor VIIa ( rFVIIa ) . Rarely , patient develop refractoriness product therapy sequential FEIBA rFVIIa recently suggest . The impetus present report hemophilia A patient high titer inhibitor ( 1300BU ) life threaten hematuria resistant repeat dos 400µg/kg rFVIIa cumulative dose 1200 µg/kg give 6-9 hour . Thrombin generation ( TG ) test vitro consistent resistance high concentration rFVIIa yield good response combination low dos rFVIIa+FEIBA . In desperate attempt control bleeding , concomitant therapy 25 U/kg FEIBA 40µg/kg rFVIIa infuse result arrest bleeding within minute . Over span one year patient successfully treat combination 200 bleeding episode muscle joint .</brief_summary>
	<brief_title>Combination Therapy Low Doses rFVIIa FEIBA Severe Hemophilia A Patients With Inhibitor Factor VIII</brief_title>
	<detailed_description>Inhibitor patient HR inhibitor eligible study enrollment . After consent blood draw ex- vivo spike rFVIIa/FEIBA combination , assay thrombin generation test . The combination yield sufficient hemostasis depict patient ' therapy future bleed episode . Following actual therapy hemostasis safety parameter monitor .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Hemophilia patient inhibitor Patients sign informed consent Patients 16 65 Patients allergic reaction adverse event previous use concentrate Patients high risk thrombosis</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>